2022
DOI: 10.1097/j.pain.0000000000002697
|View full text |Cite
|
Sign up to set email alerts
|

One size does not fit all: towards optimising the therapeutic potential of endogenous pain modulatory systems

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
4
2

Relationship

0
6

Authors

Journals

citations
Cited by 13 publications
(4 citation statements)
references
References 77 publications
0
4
0
Order By: Relevance
“…However, given the complexity and interrelatedness of these mechanisms, it is unlikely that one test will offer sufficient sensitivity and specificity for all patients. CPM is suggested to test the integrity of DNIC mechanisms only, so is unlikely to be informative of alterations in other descending control systems, such as those involved in stress-induced analgesia 11▪▪ . Other psychophysical tests, including quantitative sensory testing (QST) offset analgesia or temporal summation of pain 18–21 offer varying levels of sensitivity to detect pathology in different pain phenotypes, but they are similarly unlikely to be sufficient in isolation, nor are they expressly intended to probe descending control mechanisms.…”
Section: Endogenous Pain Control and Novel Avenues For Pharmacotherapymentioning
confidence: 99%
See 2 more Smart Citations
“…However, given the complexity and interrelatedness of these mechanisms, it is unlikely that one test will offer sufficient sensitivity and specificity for all patients. CPM is suggested to test the integrity of DNIC mechanisms only, so is unlikely to be informative of alterations in other descending control systems, such as those involved in stress-induced analgesia 11▪▪ . Other psychophysical tests, including quantitative sensory testing (QST) offset analgesia or temporal summation of pain 18–21 offer varying levels of sensitivity to detect pathology in different pain phenotypes, but they are similarly unlikely to be sufficient in isolation, nor are they expressly intended to probe descending control mechanisms.…”
Section: Endogenous Pain Control and Novel Avenues For Pharmacotherapymentioning
confidence: 99%
“…It was first recognised in the late 1970s that the brain and brainstem provide inhibitory/facilitatory control over incoming signals from the body, ultimately exerting their influence at the dorsal horn of the spinal cord. Since those early descriptions of diffuse noxious inhibitory controls (DNIC) 10 , multiple descending control mechanisms have been identified that interact to influence moment-to-moment pain experiences, depending on other competing internal and external demands 11▪▪ . Multiple neurotransmitter systems underpin these inhibitory/facilitatory influences, including gamma-aminobutyric acid (GABA), noradrenaline, serotonin and dopamine, in addition to opioidergic mechanisms 12 , offering candidate mechanisms for therapeutic intervention.…”
Section: Endogenous Pain Control and Novel Avenues For Pharmacotherapymentioning
confidence: 99%
See 1 more Smart Citation
“…To address this gap, we aimed at investigating the relationship between use of CIHA and placebo effects given the potential therapeutic prospective of endogenous pain modulation in chronic pain management (Bannister & Hughes, 2022). It should be noted that efficacy of CIHA is beyond the scope of this study.…”
Section: Introductionmentioning
confidence: 99%